Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 80

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Breast cancer metastatic

Not recruiting

Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Cervix carcinoma

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Breast cancer+5

Not recruiting

Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroestradiol F-18
  • Sponsor:GE Healthcare Limited

Breast cancer metastatic+1

Not recruiting

Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and Stereotactic Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Vychodoslovensky Onkologicky Ustav a.s.

Hormone-refractory prostate cancer

Not recruiting

Study Comparing Docetaxel Alone and Docetaxel with Radium-223 for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Radium RA 223 dichloride
  • Sponsor:Memorial Sloan Kettering Cancer Center

Prostate cancer

Not recruiting

Study on High-Intensity Focused Ultrasound and Leuprorelin Acetate for Intermediate Risk Prostate Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate
  • Sponsor:Institut Mutualiste Montsouris

Precocious puberty

Not recruiting

Study on Slowing Advanced Puberty in Girls Using Metformin, Pioglitazone, and Spironolactone

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Metformin
  • Sponsor:Hospital Universitari De Girona Doctor Josep Trueta

Infertility

Not recruiting

Study on Improving Live Birth Rates in Women Under 37 with Infertility Using cpFT During ICSI

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cpft Trifluoroacetate
  • Sponsor:Assistance Publique Hopitaux De Paris

Breast cancer+1

Not recruiting

Study on Early Breast Cancer Treatment with Palbociclib, Tamoxifen, and Exemestane for Patients with Estrogen Receptor Positive Tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Karolinska University Hospital

Colon cancer+1

Not recruiting

Study on the Impact of DPYD Gene Test on the Safety and Efficacy of Fluorouracil, Capecitabine, and Tegafur in Finnish Patients with Breast or Colon Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:HUS-Yhtymae

Hormone-refractory prostate cancer

Not recruiting

Study of ODM-208 (opevesostat) safety and effectiveness in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ODM-208
  • Sponsor:Orion Corporation

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.